Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases

详细信息    查看全文

• 作者：Gerard J. Oakley III ; MD^a ; ^b ; ^{goakley@marshall.edu" class="auth_mail" title="E-mail the corresponding author} ; Krista L. Denning ; MD^a ; Vincent Graffeo ; MD^a ; Doreen C. Griswold ; MD^a ; Adam R. Davis ; BS^a ; Linda G. Brown ; MD^a
• 关键词：Tumor ; Metastasis ; Immunohistochemistry ; CyclinD1 ; Colon adenocarcinoma
• 刊名：Pathology - Research and Practice
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：212
• 期：11
• 页码：995-1003
• 全文大小：1268 K

文摘

Tumor heterogeneity implies the possibility of significantly different expression of key pathways between primary and metastatic clones. Colon adenocarcinoma is one of the few tumors where current practice includes resection of primary and isolated organ metastases simultaneously without neoadjuvant therapy. We performed a pilot study on 28 cases of colon adenocarcinoma resected simultaneously with metastases in patients with no history of neoadjuvant therapy. We assayed matched primary and metastatic tumors from each patient with common diagnostic antibodies to Bcl-2, Cyclin D1, AMACR, and ALDH-1 by immunohistochemistry with semi-quantitative interpretation on archived formalin fixed, paraffin embedded samples. We were powered for large, consistent differences between primary and metastatic expression, and found 21 of 28 had a significant difference in expression of at least one of the four proteins, accounting for multiplicity of testing. Cyclin D1 had significantly more cases with differential metastatic:primary expression than would be expected by chance alone (p-value 0.0043), favoring higher expression in the metastatic sample. Bcl-2 and ALDH-1 had trends in this direction (p-value 0.078 each). Proportionately more cases with significant differences were identified when a liver metastasis was tested. We conclude differences in expression between metastatic and primary colon adenocarcinoma within the same patient exist, and may have therapeutic and biomarker testing consequences.